English  |  正體中文  |  简体中文  |  總筆數 :0  
造訪人次 :  51632111    線上人數 :  927
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"jia horng kao"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 456-480 / 1180 (共48頁)
<< < 14 15 16 17 18 19 20 21 22 23 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2021-09-04T06:11:31Z On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy Huang Y.-W.; Takahashi S.; Tsuge M.; Chen C.-L.; Wang T.-C.; Abe H.; Hu J.-T.; Chen D.-S.; Yang S.-S.; Chayama K.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:31Z Perspectives and control of hepatitis B virus infection in Taiwan Lin C.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:31Z Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients Wang C.-C.; Liu C.-H.; Lin C.-L.; Wang P.-C.; Tseng T.-C.; Lin H.H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:30Z Reply to: Modulation of Toll-like receptor 9 expression on monocytes of viral hepatitis patients Huang Y.-W.; Yang S.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:30Z Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir Chen G.-Y.; Su T.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:30Z Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection Cheng H.-R.; JIA-HORNG KAO; Wu H.-L.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Su T.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J.
臺大學術典藏 2021-09-04T06:11:29Z New insights into the evolutionary rate of hepatitis B virus at different biological scales Lin Y.-Y.; Liu C.; Chien W.-H.; Wu L.-L.; Tao Y.; Wu D.; Lu X.; Hsieh C.-H.; Chen P.-J.; Wang H.-Y.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏 2021-09-04T06:11:29Z Treating Immune-tolerant Hepatitis B Tseng, T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:29Z Improving clinical outcomes of chronic hepatitis B virus infection Su T.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:28Z Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection Song L.-W.; Liu P.-G.; Liu C.-J.; Zhang T.-Y.; Cheng X.-D.; Wu H.-L.; Yang H.-C.; Hao X.-K.; Yuan Q.; Zhang J.; JIA-HORNG KAO; Chen D.-S.; Chen P.-J.; Xia N.-S.
臺大學術典藏 2021-09-04T06:11:28Z Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection Hsu C.-S.; Liu W.-L.; Chao Y.-C.; Lin H.H.; Tseng T.-C.; Wang C.-C.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:28Z HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:27Z Comparison of abbott realtime HCV genotype II with versant line probe assay 2.0 for hepatitis C virus genotyping Liu C.-H.; Liang C.-C.; Liu C.-J.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:27Z Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy Liang C.-C.; Liu C.-H.; Chung C.-S.; Lin C.-K.; Su T.-H.; Yang H.-C.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:27Z Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection Tseng T.-C.; Liu C.-J.; Chen C.-L.; Yang W.-T.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:26Z Predicting hepatitis B virus (HBV) surface antigen seroclearance in HBV e antigen-negative patients with chronic hepatitis B: External validation of a scoring system Liu J.; Tseng T.-C.; Yang H.-I.; Lee M.-H.; Batrla-Utermann R.; Jen C.-L.; Lu S.-N.; Wang L.-Y.; You S.-L.; Chen P.-J.; Chen C.-J.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:26Z Systematic review: Impact of interferon-based therapy on HCV-related hepatocellular carcinoma Hsu C.-S.; Chao Y.-C.; Lin H.H.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:25Z Peginterferon plus weight-based ribavirin for treatment-na?ve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L.
臺大學術典藏 2021-09-04T06:11:25Z Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial Buti M.; Flisiak R.; JIA-HORNG KAO; Chuang W.-L.; Streinu-Cercel A.; Tabak F.; Calistru P.; Goeser T.; Rasenack J.; Horban A.; Davis G.L.; Alberti A.; Mazzella G.; Pol S.; Orsenigo R.; Brass C.
臺大學術典藏 2021-09-04T06:11:25Z Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; Chen P.-J.; Chen K.-F.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏 2021-09-04T06:11:24Z Towards an HBV cure: State-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure Zeisel M.B.; Lucifora J.; Mason W.S.; Sureau C.; Beck J.; Levrero M.; Kann M.; Knolle P.A.; Benkirane M.; Durantel D.; Michel M.-L.; Autran B.; Cosset F.-L.; Strick-Marchand H.; Tr?po C.; JIA-HORNG KAO; Carrat F.; Lacombe K.; Schinazi R.F.; Barr?-Sinoussi F.; Delfraissy J.-F.; Zoulim F.
臺大學術典藏 2021-09-04T06:11:24Z A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan Bennett H.; Waser N.; Johnston K.; JIA-HORNG KAO; Lim Y.-S.; Duan Z.-P.; Lee Y.-J.; Wei L.; Chen C.-J.; Sievert W.; Yuan Y.; Li H.
臺大學術典藏 2021-09-04T06:11:23Z Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: A nation-wide cohort study Huang Y.-W.; Wang T.-C.; Yang S.-S.; Lin S.-Y.; Fu S.-C.; Hu J.-T.; Liu C.-J.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏 2021-09-04T06:11:23Z Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Lee C.-Y.; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:23Z Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers Tseng T.-C.; Liu C.-J.; Yang H.-C.; Chen C.-L.; Yang W.-T.; Tsai C.-S.; Kuo S.F.-T.; Verbree F.C.; Su T.-H.; Wang C.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO

顯示項目 456-480 / 1180 (共48頁)
<< < 14 15 16 17 18 19 20 21 22 23 > >>
每頁顯示[10|25|50]項目